SCHEMBL1165640

SCHEMBL1165640

COc1ccc(Nc2cccc([N+](=O)[O-])c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.63
AKR1C2 P52895 1/20 0.63
MAPT P10636 7/20 0.62
ALDH1A1 P00352 4/20 0.62
MAPK1 P28482 3/20 0.62
TDP1 Q9NUW8 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
LMNA P02545 2/20 0.60
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
HTT P42858 3/20 0.59
ABCG2 Q9UNQ0 1/20 0.58
NFE2L2 Q16236 1/20 0.57
CTSV O60911 1/20 0.56
CTSL P07711 1/20 0.56
PKM P14618 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468622 0.89 AKR1C3 (0.64) AKR1C3AKR1C2MAPTMAPK1TDP1
SCHEMBL1195949 0.84 MAPT (0.68) AKR1C3AKR1C2MAPTALDH1A1MAPK1
SCHEMBL394734 0.83 KMT2A (0.67) MAPTALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL9243623 0.83 KMT2A (0.59) MAPTALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL2717131 0.82 HPGD (0.69) MAPTALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL1734464 0.81 ABCG2 (0.57) AKR1C3AKR1C2MAPTALDH1A1MAPK1
SCHEMBL7833210 0.80 KMT2A (0.64) AKR1C3AKR1C2MAPTALDH1A1MAPK1
SCHEMBL13302357 0.80 RAB9A (0.74) MAPTALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL30234162 0.80 KIF11 (0.57) MAPTALDH1A1L3MBTL1NPC1LMNA
SCHEMBL26310363 0.80 KIF11 (0.57) MAPTALDH1A1L3MBTL1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB AKR1C3 3927/4885AKR1C2 3647/4885MAPT 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.